mycophenolate mofetil


Also found in: Dictionary, Acronyms, Wikipedia.

mycophenolate mofetil

an immunosuppressant used to prevent rejection of allogeneic cardiac, hepatic, and renal transplants. It is administered orally or intravenously.
indications It is used to prevent rejection of organ transplants and for prophylaxis of organ rejection in allogenic cardiac transplants.
contraindications Known hypersensitivity to this drug or to mycophenolic acid prohibits its use.
adverse effects Life-threatening effects are leukopenia, thrombocytopenia, anemia, pancytopenia, renal tubular necrosis, and lymphoma. Other adverse effects are arthralgia, muscle wasting, and stomatitis. Common side effects are diarrhea, constipation, nausea, vomiting, rash, dyspnea, respiratory infection, increased cough, pharyngitis, bronchitis, pneumonia, tremor, dizziness, insomnia, headache, fever, peripheral edema, hypercholesterolemia, hypophosphatemia, edema, hyperkalemia, hypokalemia, hyperglycemia, urinary tract infection, hematuria, hypertension, chest pain, and nonmelanoma skin carcinoma.

mycophenolate mofetil

A mycophenolic ester used as a therapeutic immunosuppressant, which is similar to, but less toxic than, azathioprine. Mycophenolate mofetil inhibits purine metabolism in T and B cells, and lymphocyte proliferation in vitro.

Indications
Prevent or manage GVHD, rejection of heart, kidney, lung and other allograft transplants, autoimmune disorders (e.g., Behçet  disease, pemphigus vulgaris, systemic lupus erythematosus).
 
Adverse effects
Hyperglycaemia, hypercholesterolaemia, increased BUN, potassium, leukopaenia, anaemia, diarrhoea, emesis.

mycophenolate mofetil

Immunology A mycophenolic ester derivative that may be better than azathioprine as an immunosuppressive purine analogue; it inhibits purine metabolism in T and B cells, and lymphocyte proliferation in vitro; MMF is used to prevent or manage GVHD, rejection of heart, kidney, lung and other allograft transplants, autoimmune disorders Adverse effects Leukopenia, anemia, diarrhea, emesis. See Heart transplant, Kidney transplant, Lung transplant.

mycophenolate mofetil

An IMMUNOSUPPRESSANT DRUG used to help to prevent rejection of the donated organ after kidney grafting. The drug has also been found to be more effective than cyclophosphamide in causing remission in lupus glomerulonephritis. A brand name is Cellcept.

mycophenolate mofetil

(mī´kōfen´olāt mof´ətil´),
n brand name: CellCept;
drug class: immunosuppressant;
action: selective inhibitor of inosine monophosphate dehydrogenase, thereby preventing the synthesis of guanosine nucleotide and resulting in cytostatic effect on T and B lymphocytes;
uses: prophylaxis of organ rejection in patients receiving allogenic renal transplants (in combination with cyclosporine and corticosteroids).
References in periodicals archive ?
Mycophenolate mofetil was the other immunosuppressive medication used.
Mycophenolate mofetil or cyclophosphamide are usually used as the first line treatment for nephritis, and in either case, corticosteroids are added.
8 mg/dL, and her SLE was well controlled on low-dose mycophenolate mofetil and prednisone.
Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), a potent and selective noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPD), a key enzyme in the de novo synthesis of guanosine nucleotides.
Therefore, the individual effects of tacrolimus and mycophenolate mofetil could not be assessed.
There has been mounting enthusiasm in recent years for the use of mycophenolate mofetil (MMF) in the treatment of SLE.
Mycophenolic acid (MPA) [1] is the pharmacologically active form of the immunosuppressant prodrug mycophenolate mofetil.
All recipients were maintained on standard immunosuppression consisting of mycophenolate mofetil, cyclosporine and prednisone.
Johns wort was halted, and the cydosporine was increased from 125 mg twice daily to 150 mg twice daily One-gram daily bolus doses of corticosteroids also were given for 3 days, and mycophenolate mofetil was substituted for the azathioprine.
The clinical abstracts examine the impact of BENLYSTA on patients with SLE, including its efficacy and safety, its early clinical improvement and its impact in patients also being treated with mycophenolate mofetil and/or corticosteroids.
The drug is approved for use with other immunosuppressants, including basiliximab, mycophenolate mofetil, and corticosteroids.